Ugro Capital files NCLT application for Profectus Capital merger

BANKINGFINANCE
Whalesbook Corporate News Logo
AuthorKavya Nair|Published at:
Ugro Capital files NCLT application for Profectus Capital merger

Ugro Capital has filed a Company Application with the NCLT, Mumbai, for its merger with Profectus Capital. This is a key legal step after board and stock exchange approvals.

Ugro Capital Files NCLT Application for Profectus Capital Merger

Ugro Capital Limited has officially moved forward with its proposed merger with Profectus Capital Private Limited by filing a Company Application with the National Company Law Tribunal (NCLT) in Mumbai on July 16, 2026. This filing marks a significant legal step in the amalgamation process.

What just happened

The company submitted a mandatory Company Application to the NCLT, Mumbai Bench, for the merger scheme.

Why this matters

This NCLT filing is a crucial legal prerequisite for the proposed amalgamation of Profectus Capital into Ugro Capital, advancing the transaction towards completion.

The backstory

The merger scheme was previously approved by Ugro Capital's board of directors on January 8, 2026. Subsequently, the company received observation letters from the stock exchanges on July 10, 2026, indicating no objections at that stage.

What changes now

With the NCLT application filed, the merger process is now under judicial review and requires further approvals.

Risks to watch

The scheme remains conditional and is subject to final sanction from the NCLT and necessary approvals from shareholders and creditors.

Peer comparison

Mergers and acquisitions are common in the financial services sector as companies seek consolidation and enhanced market positioning.

Context metrics (time-bound)

  • Board approval: January 8, 2026
  • Stock exchange observations: July 10, 2026
  • NCLT filing: July 16, 2026

What to track next

Investors should monitor future disclosures from Ugro Capital regarding the timeline for NCLT hearings, potential shareholder and creditor meetings, and final regulatory approvals.

Disclaimer: This article is published for informational purposes only. This is not a buy sell recommendation.